Delphi (DLPH - Get Report) was downgraded to underweight from overweight at Morgan Stanley. $59 price target. The company is seeing slower growth and realizing lower margins, given increased competition, Morgan Stanley said.
Greif (GEF - Get Report) was downgraded to equal-weight from sector weight at Keybanc. $47 price target. Organic sales growth will likely remain weak and currency should be a drag in 2017, Keybanc said.
Pfizer (PFE - Get Report) was upgraded to overweight from equal-weight at Barclays. $38 price target. The company should be able to use foreign cash to boost returns and the oncology business will drive growth, Barclays said.